<DOC>
	<DOC>NCT01735175</DOC>
	<brief_summary>The study will assess the efficacy of LA-EP2006 compared to Peg-Filgrastim with respect to the mean duration of severe neutropenia during treatment with myelosuppressive chemotherapy in breast cancer patients.</brief_summary>
	<brief_title>Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and NeulastaÂ®</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>histologically proven breast cancer eligible for six cycles of neoadjuvant or adjuvant chemotherapy concurrent or prior chemotherapy for breast cancer concurrent or prior anticancer treatment for breast cancer such as endocrine therapy, immunotherapy, monoclonal antibodies, and/or biological therapy concurrent prophylactic antibiotics previous therapy with any GCSF (granulocytecolony stimulating factor) product Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Prevention of neutropenic complications in breast cancer patients</keyword>
	<keyword>Pegfilgrastim,</keyword>
	<keyword>G-CSF,</keyword>
	<keyword>neutropenia,</keyword>
	<keyword>breast cancer,</keyword>
	<keyword>myelosuppressive chemotherapy,</keyword>
	<keyword>supportive care</keyword>
</DOC>